Singapore-based biopharmaceutical company ASLAN Pharmaceuticals has announced positive interim data from its Phase II TREK-DX study of eblasakimab, a drug candidate for moderate-to-severe atopic dermatitis (AD) in adults.

The randomised, double-blind, placebo-controlled trial enrolled 75 subjects across North America and Europe.

It is designed to assess eblasakimab’s efficacy and safety in people who had previously received the dupilumab treatment but did not finish it for various reasons.

The study includes a 16-week treatment period followed by an eight-week safety follow-up.

The percentage change in the Eczema Area Severity Index (EASI) score from baseline to week 16 is the trial’s primary efficacy endpoint.

Key secondary endpoints include the proportion of subjects attaining Investigator Global Assessment (vIGA) score of zero (clear) or one (almost clear), as well as a 75% or greater reduction in EASI (EASI-75) score.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An interim analysis data from 22 patients showed a statistically significant change in the primary endpoint compared to placebo.

In addition, 73.3% of subjects treated with eblasakimab achieved an EASI-75 response, as opposed to 14.3% of patients given placebo.

By the end of week 16, subjects in the eblasakimab arm experienced an 86.9% mean reduction in their EASI score from baseline, significantly higher than the 51.2% reduction observed in the placebo group.

Eblasakimab treatment was well-tolerated in the trial, without any new safety concerns reported.

ASLAN Pharmaceuticals CEO Dr Carl Firth said: “Most patients on eblasakimab achieved EASI-90 and vIGA of 0 or 1 after just 16 weeks of treatment, with numbers unprecedented in other biologics AD studies.

“Notably, in patients that previously had an inadequate response to dupilumab, two-thirds achieved EASI-90 and vIGA 0 or 1 when treated with eblasakimab.”

Last May, ASLAN Pharmaceuticals announced it had enrolled the final subject in the TREK-AD trial of eblasakimab to treat moderate-to-severe AD.